Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohnʼs disease population

Schoepfer, Alain M.; Vavricka, Stephan R.; Binek, Janek; Felley, Christian; Geyer, Martin; Manz, Michael; Rogler, Gerhard; de Saussure, Philippe; Sauter, Bernhard; Seibold, Frank; Straumann, Alex; Michetti, Pierre (2010). Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohnʼs disease population. Inflammatory bowel diseases, 16(6), pp. 933-938. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1002/ibd.21127

Full text not available from this repository. (Request a copy)

Switzerland was the first country to approve certolizumab pegol (Cimzia, CZP) for the treatment of patients with moderate to severe Crohn's disease (CD) in September 2007. This phase IV study aimed to evaluate the efficacy and safety of CZP in a Swiss multicenter cohort of practice-based patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology

UniBE Contributor:

Seibold, Frank Werner

ISSN:

1078-0998

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:07

Last Modified:

03 May 2014 01:27

Publisher DOI:

10.1002/ibd.21127

PubMed ID:

20014021

Web of Science ID:

000278514100009

URI:

https://boris.unibe.ch/id/eprint/83 (FactScience: 195328)

Actions (login required)

Edit item Edit item
Provide Feedback